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INTRODUCTION
Diabetes mellitus (DM) is a critical public health 
issue globally and its prevalence is increasing mostly 
in developing countries.[1‑4] The number of diabetics 
between 20 and 79 years of age is estimated to be 415 
million people in the world and is expected to rise to 
642 million in 2040.[5] Iran is one of the most populous 
countries of the Middle East and the prevalence 
of diabetes in Iran ranges from 7.7% to 14% in the 
population aged over 20 years.[2,6,7] In addition, it is 
estimated that Iran would take the second place in 
diabetes annual growth after Pakistan.[2]
Diabetic retinopathy (DR) is one of the major 
complications of diabetes and leading cause of visual 
impairment or blindness.[8‑16] Evidence reveals that 
nearly all type I and 60% of type II diabetic patients 
develop some degrees of retinopathy 20 years after 
diagnosis.[17] Given the increasing number of diabetics 
worldwide, it is expected that the prevalence of DR 
increases especially in developing countries.[14] Similarly, 
DR is a major cause of visual impairment and loss in 
Iran.[10,11,18,19] Based on the current data, 37% and 29.6% 
of diabetic cases have some degrees of DR in Tehran and 
Yazd provinces, respectively.[11,19] On the other hand, 
therapeutic interventions can prevent the development 
of severe visual impairment caused by DR in up to 90% 
of cases.[20]
National clinical practice guidelines (CPGs) 
comprise thorough clinical recommendations based 
on valid evidence and are adapted considering their 
safety, efficacy, cost of diagnostic or therapeutic 
interventions, and the nation’s needs. These guidelines 
increase the efficacy of interventions and provide 
equity in access to treatment for all members of the 
society. Since CPGs focus on a particular problem, for 
instance one disease, they can help both the physicians 
and the patients in making an appropriate decision. 
These instructions can also be effective in guiding 
health care policy makers at a national scale. Therefore, 
clinical guidelines increase both accessibility and 
quality of health care services.[21,22]
Paragraph D, article 32 of the Fifth 5‑Year Development 
Plan of Iran and the Strategic Objective No. 75 of the 
Iranian Ministry of Health and Medical Education 
emphasize on the development, adaptation and 
implementation of clinical practice guidelines, and 
extension of health care services and development of 
evidence based health care at a national level.[23,24]
Considering the growing prevalence of diabetes 
and DR in Iran, its impact on public health, costs 
imposed on the health care system, and in order to 
establish the objectives of the Fifth 5‑Year Development 
Plan of Iran and the Strategic Objective No. 75 of the 
Iranian Ministry of Health and Medical Education, DR 
CPGs were customized for Iranian population under 
supervision of the Office for Healthcare Standards, 
Deputy of Curative Affairs, Iran Ministry of Health 
and Medical Education.
METHODS
The DR CPGs were adapted for Iranian population in 
the Knowledge Management Unit (KMU), Ophthalmic 
Research Center, Shahid Beheshti University of Medical 
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Sciences, Tehran, Iran. The adapting team included the 
director and the research deputy of the Ophthalmic 
KMU, five vitreoretinal specialists, a PhD by research 
candidate (a Master’s of Science degree holder in 
Optometry), a Master’s of Science degree holder in 
biostatistics, and the head of the office for healthcare 
standards, Deputy of Curative Affairs, Iran Ministry of 
Health and Medical Education.
Searching and Identifying the Current 
Clinical Guidelines
The National Guidelines Clearinghouse (NGC), Guidelines 
International Network (G‑I‑N), National Institute for Clinical 
Excellence (NICE), Scottish Intercollegiate Guidelines 
Network (SIGN), New Zealand Guidelines Group, National 
Health and Medical Research Council (NHMRC), Cochrane, 
Bandolier, CADTH, Trip Database, PubMed (Clinical 
queries), Google Scholar, SID, Medlib, Magiran were the 
databases and websites that were explored in order to 
extract the relevant clinical guidelines.
Screening the Guidelines
The extracted guidelines were screened using the AGREE 
(appraisal of guidelines for research and evaluation) 
tool.[25] Ultimately, 3 DR guidelines by the Royal College 
of Ophthalmologists (2013),[26] American Academy of 
Ophthalmology (Preferred Practice Pattern 2012),[20] and 
Australian Diabetes Society (2008)[27] were selected as the 
reference CPGs.
M e t h o d s  U s e d  f o r  C u s t o m i z i n g 
Recommendations
Evaluating and appraising the reference CPGs’ 
recommendations
Initially, 20 questions on DR were designed and the 
questions’ components (PICO; Patient, Intervention, 
Comparison, Outcome) were entered in Table 1. 
Subsequently, the answers to the questions were 
extracted from the reference CPGs and the responses 
were recorded in the same table.
In the process of extraction and analysis of the 
responses, the questions were evaluated once again 
and broken down into smaller questions if necessary, 
and all the above‑mentioned steps were repeated for 
each.
Analyzing the supporting evidence
The details of each evidence were recorded in Table 2. 
Tables 3 shows the levels of evidence. 
Evaluating the recommendations in terms of clinical benefits 
and adaptability
After completing Tables 1 and 2, the customization team 
composed the clinical recommendations respecting the 
clinical benefits including cost, benefits, and side effects 
and then recorded those in Table 4. Consequently, the 
recommendations were revised in Table 5 according 
to three customization criteria: 1- applicability (access 
to proper equipments, skills at using them, and their 
affordability for patient), 2‑ acceptability (patient’s 
preferences, cultural considerations and patient’s 
acceptability of the therapeutic protocol), 3‑compatibility 
(similarity between patient’s characteristics/disease 
type and their interference with studied evidence).
Consensus
All recommendations together with complementary 
instructions and Tables 1, 2, 4 and 5 were sent to the 
chairs of the retina and vitreous departments at Ahvaz 
Jundishapur, Gilan, Iran, Isfahan, Mashad, Tabriz, 
Tehran, Shahid Beheshti, Shahid Sadoughi, Shiraz 
and Zahedan Universities of Medical Sciences. As the 
experts in the field of DR, they were asked to score 
each recommendation in terms of clinical benefits and 
customizability, and to provide a total score for each 
recommendation at the end. In addition, they were asked 
to provide any further evidence that could potentially 
change the recommendation.
Analyzing the consensus scores and developing the final 
recommendations
Experts scored the recommendations based on the RAM 
model.[28] The scores were analyzed and the agreement 
level for each recommendation was identified. The 
agreed recommendations were considered as the final 
Table 1. Analysis of recommendations
Question P I (E) C O Type of 
question
Referenced 
guidelines
Phrase of 
recommendation
Level of 
evidence
Inconsistency of 
recommendations
Technical 
breakthrough
New 
systematic 
review
New 
Studies
G1
G2
G3
P, patient or population; I, intervention; E, exposure; C, comparison; O, primary outcomes; G1, American Academy of Ophthalmology (2012); 
G2, Royal College of England (2013); G3, Australian Diabetes Association (2008)
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recommendations. The experts discussed the non‑agreed 
ones in a session and after applying the required changes, 
the final recommendations were developed.
All customized recommendations are presented in the 
results section of this article along with their reference 
numbers and their evidence levels (EL).
RESULTS
Recommendations for Screening, Risk Factors 
and Follow‑up
Screening and examination
As reported by the screening programs in the US, 
England, and Australia, the modality of choice 
to screen for DR is retinal digital imaging with 
mydriasis which has a sensitivity of 73‑96% and 
specificity of 78‑99%. Considering its feasibility, this 
test is recommended for screening of DR in Iran as 
well.[29‑36]
(EL: I)
Considering the few reported side effects of 
tropicamide eye drop 1% (1 to 6 in 20,000 cases in 
different studies) and to improve the sensitivity of 
funduscopy, it can be used to provide mydriasis for DR 
screening in diabetic patients except in those with history 
of glaucoma.[37‑44]
(EL: I)
Risk factors
Duration of diabetes
Regardless of the type, those with longer disease duration 
are at greater risk for development and progression of 
DR. Therefore:
• Funduscopy is strongly recommended for type II 
diabetics at their first eye examination.
• It is recommended that type I diabetics undergo 
funduscopy 3 to 5 years after diagnosis of 
diabetes.[17,45‑54]
(EL: II)
If patients are found to have signs of retinopathy, a 
follow‑up plan should be set up based on the severity 
of the retinopathy.
(EL: Consensus ‑ IV)
Blood sugar
Although tight glycemic control does not necessarily 
prevent the development of DR, it is recommended 
that diabetic patients control blood glucose and HbA1C 
levels in order to reduce the risk of DR progression and 
consequently the need for treatment.[45,55‑60]
(EL: I)
Blood pressure
Target systolic blood pressure of less than 130 mmHg 
is recommended for diabetic patients to slow down the 
progression of DR.[61‑65]
(EL: I)
Serum lipids
• Elevated serum lipid levels increase the risk of 
development and progression of DR. Therefore, 
control of serum lipids with statins and fibrates is 
recommended in diabetic patients.[66‑81]
(EL: I)
• Hyperlipidemia has been identified as a risk 
factor for exudative diabetic macular edema. 
Therefore, control of serum lipids is recommended 
as a preliminary therapeutic measure in diabetic 
patients.[66‑81]
(EL: II)
Table 2. Analysis of the supporting evidence
Evidence code P I (E) C O Effect size Statistical values Level of recommendation
P, patient or population; I, intervention; E, exposure; C, comparison; O, primary outcomes
Table 3. Level of evidence
Level of 
evidence
Type of evidence
I Meta‑analysis 
Systematic reviews
Randomized clinical trial 
II Clinical trial
Well‑designed cohort
Well‑designed case control
Cross‑sectional 
III Surveys
Descriptive
Case series studies
IV Experts opinion, consensus
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Kidney disorders
• It is recommended that the patients with diabetes 
and coexisting kidney disease undergo careful retinal 
examination due to the risk of developing DR (up to 
58%)[82]
• It is recommended that the patients with advanced DR 
undergo thorough renal function evaluation due to the 
risk of developing kidney disorders (about 15%).[82]
(EL: II)
Vitamin D
As vitamin D deficiency can be associated with progression 
of DR, consultation with a specialist (endocrinologist, 
gastroenterologist, or nephrologist) is warranted 
for diabetic patients with vitamin D deficiency and 
coexisting renal and gastrointestinal problems.[83‑85]
(EL: II)
Smoking
Cigarette smoking has been associated with lower 
incidence of DR, however, considering the higher rate 
of morbidity and mortality among smokers, smoking 
cessation is recommended.[64,77,86‑94]
(EL: II)
Pregnancy
A two‑fold increase in the risk of DR development 
during pregnancy warrants educating diabetic women 
planning a pregnancy. In addition, they should be 
monitored by regular blood glucose checks and 
retinal examination during and after the course of 
pregnancy.[95‑102]
A thorough assessment of DR is recommended before 
planning a pregnancy.[95‑102]
(EL: I)
Genetics
It appears that certain genes are involved in the 
development and progression of DR that could vary by 
ethnicity and geographical origin.[103‑122]
(EL: II)
Therefore, it is recommended that patients with 
positive family history of DR undergo more frequent 
eye examinations.
(EL: Consensus ‑ IV)
Coexisting eye diseases with diabetes
• Other diabetic eye diseases such as cataract, optic 
neuropathy, extraocular muscle paralysis, rubeosis 
iridis, and the delay in corneal epithelium healing 
should be taken into consideration in patients with 
DR.[123‑126]
• It is recommended to examine the iris and angle 
for the presence of neovascularization prior to 
initialization of mydriatic eye drops.[123‑126]
• Diabetic candidates for keratorefractive surgery 
should be well informed about the delayed corneal 
epithelium wound healing prior to surgery.[123‑126]
(EL: II, Consensus ‑ IV)
Referral and follow‑up approach in patients with diabetes
It is recommended to examine the patients with R2 
level DR (preproliferative) according to the National 
Screening Committee Severity Classification System 
or level 43 (moderate NPDR) according to the Early 
Treatment Diabetic Retinopathy Study (ETDRS) Severity 
Classification System at 4-month intervals.[37,63,127‑131]
Diabetic patients should be referred to and followed 
by ophthalmologists according to the following 
protocol:[37,63,127‑131]
• All type 2 diabetic patients should undergo fundus 
examination (with pupil dilatation) and visual acuity 
measurements at the time of diagnosis and at least 
every 2 years thereafter.
(EL: I)
• Patients with signs of nonproliferative DR (NPDR) 
should be examined annually or every 3‑6 months 
depending on the severity of DR.
(EL: III)
• Patients with mild to moderate NPDR should be 
examined closely for sight threatening retinopathy.
(EL: I)
Table 4. Clinical benefits of the recommendations
Question Phrase of 
recommendation
Level of 
evidence
Costs Clinical effectiveness of the 
recommendation
Clinical effectiveness 
score
Side 
effects
Side 
benefits
Effect 
size
Low Moderate High
P, patient or population; I, intervention; E, exposure; C, comparison; O, primary outcomes; Low: Score 1‑3; Moderate: Score 4‑6; High: Score 
7‑10
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• High-risk diabetic patients (long diabetes duration, 
poor blood glucose control, high blood pressure or 
high serum lipids) should be examined annually even 
in the absence of DR.
(EL: I)
• Children with prepubertal onset of diabetes should 
be assessed for DR when they reach puberty.
(EL: III)
• Diabetic women who become pregnant should 
undergo a comprehensive eye examination in the 
first trimester and be monitored closely throughout 
pregnancy.
(EL: I)
Recommendations for Diagnosis
Retinal imaging
Indications for fluorescein angiography
It is recommended that patients with DR undergo 
fluorescein angiography in the following conditions:[132‑135]
• In cases where funduscopic findings cannot justify 
the visual impairment (to rule out macular ischemia).
(EL: III)
• To identify leaking lesions and capillary non-perfusion 
areas that cannot be detected clinically.
(EL: II)
• To evaluate the macular capillary network
(EL: I)
Precautions for fluorescein angiography
• It is recommended that patients with known history 
of cardiovascular diseases, allergy, and lung or 
kidney disorders have appropriate consultation 
before undergoing fluorescein angiography.
• Fluorescein angiography should be carried out where 
equipments for resuscitation, atropine and adrenaline 
are available.[97,136‑143]
• In patients with prior hand, axillary or breast lymph 
node dissection, dye injection in the ipsilateral side 
is contraindicated.[97,136‑143]
(EL: Consensus ‑ IV)
Different types of fluorescein angiography
Wide-field fluorescein angiography is superior in cases with 
peripheral retinal lesions as it could alter the classification 
of the DR and therapeutic and follow‑up approaches.
(EL: II)
Availability of wide-field fluorescein angiography can be 
limited to the major ophthalmology centers.[144,145]
(EL: Consensus ‑ IV)
Other imaging modalities
New imaging modalities for evaluation of DR 
include optical coherence tomography (OCT), retinal 
thickness analysis (RTA) techniques, and fundus 
autofluorescence (FAF).[146‑173]
• Due to the particular properties of OCT such 
as demonstrating different layers of retina, the 
use of OCT is recommended in the following 
conditions:
o To determine the macular thickness in diabetic 
macular edema (before and after treatment)
o To detect vitreoretinal traction or any membrane 
on the macula
• Due to the particular properties of new fluorescein 
angiography techniques (SLO [Scanning Laser 
Ophthalmoscopy] Angiography) such as high‑speed 
imaging, high resolution, possibility of digitally 
storing the images, and integrating the patients’ data 
from different medical centers, it is suggested these 
imaging modalities be available in the majority of 
public and private settings.
• FAF can investigate functional changes in retinal 
pigment epithelium (RPE) without the injection.
(EL: III)
Classification of DR and diabetic macular edema
The most appropriate classification system (severity 
grading) of DR and diabetic macular edema (DME) 
could be selected based on the level of health care service 
offered. Due to the lower complexity, the lower‑level 
health care provider can utilize the International Clinical 
Table 5. Adaptability of the recommendations (external validity)
Question P I C O Type of the 
question
Phrase of 
recommendation
Adaptability of the recommendation Adaptation 
score
Total 
scoreApplicability Acceptability Compatibility/
External 
validity
Low Low
Moderate Moderate
High High
P, patient or population; I, intervention; E, exposure; C, comparison; O, primary outcomes; Low: Score 1‑3; Moderate: Score 4‑6; High: Score 
7‑10
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Disease Severity Scale and the subspecialty eye care 
centers can use the ETDRS severity scale to classify the 
severity of DR and macular edema.[29‑32,127,174‑186]
(EL: IV)
Recommendations for Treatment
Laser therapy
Indications for panretinal photocoagulation (PRP)
According to Diabetic Retinopathy Study (DRS), PRP 
should be performed at the high‑risk proliferative DR 
(PDR) stage. However, early PRP may be considered 
for severe NPDR and early PDR in the following 
conditions:[98,135,187‑214]
1. Elderly diabetes type II patients.
2. Prior to cataract surgery.
3. In one‑eyed patients where the vision of the other eye 
was lost due to PDR.
4. Patients who cannot be regularly examined and 
followed.
5. Pregnancy.
(EL: I)
• If possible, PRP should be delivered on the same day 
of the diagnosis of high‑risk PDR and if not, within 
2 weeks from the time of diagnosis.
(EL: II)
• PRP should be postponed until clinically significant 
macular edema (CSME) is treated.
(EL: II)
• Coexisting high-risk PDR and CSME should be treated 
with combined PRP plus intravitreal antivascular 
endothelial growth factor (VEGF) injection or macular 
laser photocoagulation (MPC).
(EL: Consensus ‑ IV)
• In cases with fresh vitreous hemorrhage, PRP 
is usually applied after intravitreal injection of 
anti‑VEGF when the ocular media is clear.
(EL: Consensus ‑ IV)
• In patients with florid type DR, PRP may be applied 
with shorter intervals (3‑5 days between PRP sessions 
instead of 1‑4 weeks).
(EL: Consensus ‑ IV)
• Patients should be followed every 1-4 weeks during 
the course of PRP and every 2‑4 months thereafter 
until regression of the neovessels and a stable 
condition is obtained. (ETDRS).
(EL: I)
• In patients with shallow anterior chamber who are 
predisposed to acute glaucoma attack, YAG laser 
peripheral iridotomy should be performed before PRP.
(EL: Consensus ‑ IV)
• In patients who are unable to maintain eye fixation 
during PRP such as those with nystagmus, retrobulbar 
anesthesia may be considered in order to avoid 
unwanted macular burns.
(EL: Consensus, IV)
• Patients should be informed about the possible 
complications of PRP such as visual field restriction and 
reduced amplitude of accommodation before treatment.
(EL: Consensus ‑ IV)
Indications of macular laser treatment
Macular laser photocoagulation should be considered 
in the following conditions:[135,191,215‑218]
• Presence of clinically significant macular edema 
(CSME) according to ETDRS.
(Most recent studies recommend intravitreal injection 
of anti‑VEGF in cases with center involving macular 
edema and visual acuity of less than 20/30 to 20/40; 
however, if the macular center is spared and visual 
acuity is higher than 20/30 to 20/40, macular laser 
photocoagulation can be applied.)
(EL: I)
• Any of the following conditions even in the absence 
of CSME features:
o Progression of macular edema towards the central 
parts of the macula
o Patients who cannot be followed every 3 months
o Cataract surgery candidates with leaking macular 
lesions may receive macular laser treatment 
preoperatively.
o Permanent vision loss in the fellow eye due to 
CSME.
o In order to prevent aggravation of macular edema, 
PRP candidates with coexisting DME should 
receive intravitreal anti‑VEGF injection prior to 
laser treatment.
(EL: I, II)
Follow‑up after macular laser photocoagulation
• According to DRS and ETDRS, patients should be 
followed at 2‑4 month intervals after macular laser 
treatment; decision for retreatment will be based 
upon visual acuity (20/30 or 20/40) and involvement 
of the central macula thereafter.[135,215,216]
(EL: I)
New laser therapy techniques
New laser treatment techniques can minimize the 
damage to the internal retinal layers and include the 
followings:[219‑231]
• Minimally invasive subthreshold laser
• Pattern automated scanner laser (PASCAL)
(EL: I)
Recommendation: Considering the lower risk of 
retinal damage with minimally invasive subthreshold 
technique, a limited number of laser machines equipped 
with these technologies are recommended to be available 
in ophthalmology centers.[219‑231]
(EL: IV – Consensus)
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Intravitreal injection
Indications
Intravitreal injection of anti‑VEGF drugs is recommended 
in the following conditions:[169,232‑326]
• Diabetic patients with diffuse macular edema and 
poor prognosis for focal laser treatment
• Patients with PDR or florid PDR and no response to 
laser therapy
• Patients with neovascularization of iris (NVI) and 
neovascular glaucoma (NVG) 
• For patients with concomitant DR and cataract, 
consultation with a retinal specialist may be 
considered prior to cataract surgery whether 
intravitreal injection should be carried out at the time 
of cataract surgery
(EL: I)
Intravitreal injection before vitrectomy
• Patients with PDR and active neovascularization 
who have been planned for vitrectomy may receive 
intravitreal anti‑VEGF injection within one week 
before surgery to minimize intraoperative and early 
postoperative bleeding.[327]
 (EL: I)
• Patients with advanced DR and active fibrovascular 
tissue who are vitrectomy candidates may receive 
intravitreal anti‑VEGF injection within one week 
before the surgery to minimize the risk of bleeding 
during and after the surgical procedure.[328‑332]
(EL: I)
• Extensive fibrovascular tissue increases the risk of 
traction retinal detachment following intravitreal 
injection of anti‑VEGF drugs; the time interval 
between the injection and vitrectomy should be not 
more than 2‑3 days in such cases.[328‑334]
(EL: II)
Intravitreal agents
None of the intravitreal anti‑VEGF agents is preferred 
over the others and the treatment choice depends on the 
availability and cost.[215,240,244,247,284,302,303,315,316,318,321,332‑333]
(EL: Consensus ‑ IV)
Complications
Complications of intravitreal injection treatment:
• Specific potential complications:
o Anti‑VEGF drugs: Thromboembolic events, blood 
pressure elevation, myocardial infarction (MI) and 
stroke.
Recommendation: Patients with the past history of MI, 
stroke, thromboembolism, or uncontrolled hypertension, 
should receive intravitreal anti‑VEGF injection after 
consultation with a cardiologist.[238,239,307,333,335,336]
(EL: I)
Recommendation: Intravitreal triamcinolone injection 
is not recommended for phakic eyes with the past history 
of glaucoma.[238,239,307,333,335‑337]
(EL: I)
• General complications:
Endophthalmitis, retinal detachment, lens damage 
and cataract, vitreous hemorrhage, subconjunctival 
hemorrhage and pain.
Recommendation: Intravitreal injection should be carried 
out under aseptic conditions to prevent endophthalmitis. In 
addition, the anatomy of the eye should be kept in mind to 
minimize the risk of damage to ocular tissues.[238,239,307,333,335‑337]
(EL: IV)
Recommendation: Intravitreal anti‑VEGF injection is not 
recommended in eyes with advanced PDR and significant 
fibrous proliferation due to the risk of traction retinal 
detachment except in vitrectomy candidates.[238,239,307,333,335‑337]
(EL: II)
Vitrectomy
Indications
Vitrectomy is recommended for diabetic eyes in the 
following conditions:[157,338‑350]
• Vitreous opacity
o Severe non‑clearing, recurrent vitreous hemorrhage
• Retinal detachment (RD)
o Tractional RD involving or threatening the 
macula
o Combined rhegmatogenous and tractional RD
• Diffuse CSME with taut hyaloid face and no 
response to previous intravitreal injections and laser 
photocoagulation
• Active and extensive fibrovascular proliferation
(EL: IV)
Considerations
• Early vitrectomy is recommended in the following 
conditions:
o Severe vitreous hemorrhage in patients with diabetes 
type I (EL: I)
o Patients with very poor vision (5/200) and severe 
vitreous hemorrhage (EL: I)
o Active fibrovascular proliferation (EL: II)
o Severe PDR refractory to PRP (EL: I)
Further recommendation
Studies have shown that while stopping anti‑coagulant 
medications decreases the risk of vitreous hemorrhage 
during vitrectomy, at the same time it increases 
mortality. Therefore, decision regarding maintenance or 
perioperative discontinuation of anticoagulation therapy 
should be made before vitrectomy by having appropriate 
consultations about patients’ systemic conditions.[351‑353]
(EL: II)
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Cataract surgery in diabetic patients
Patients should undergo thorough retinal examination 
prior to the surgery.[261‑263,354‑370]
(EL: II)
Coexisting PDR should be treated with PRP 
preoperatively if media is clear. However, in eyes with 
poor visualization due to cataract, fundus examination 
should be performed as soon possible following cataract 
surgery.[261‑263,354‑370]
(EL: I)
Patients with DME should receive intravitreal 
injection of steroid or anti‑VEGF preoperatively to lower 
the risk of DME aggravation.[261‑263,354‑370]
(EL: I)
Patients should undergo more frequent retinal 
examinations postoperatively due to their increased risk 
for progression of DR.[261‑263,354‑370]
(EL: II)
OCT should be done postoperatively to monitor 
diabetic macular edema.[261‑263,354‑370]
(EL: II)
Diabetic patients who are cataract surgery 
candidates should be well informed about the risk of 
DR progression and probable consequent decreased 
vision and the necessity of frequent eye examination 
postoperatively.[261‑263,354‑370]
DISCUSSION
Considering the high prevalence of DM and the role 
of DR as a leading cause of visual impairment and 
blindness, clinical practice guidelines for DR was 
adapted for Iranian population at the Knowledge 
Management Unit, Ophthalmic Research Center, 
Shahid Beheshti University of Medical Sciences, 
Tehran, Iran at the request of the Ministry of Health 
and Medical Education to promote the diagnostic 
and therapeutic services and enhance community 
access to evidence‑based eye care.[10,11,18,371] Different 
management aspects of DR including screening, risk 
factors, follow‑up, diagnosis and treatment were taken 
into account in this guideline.
The retinal experts reached consensus for the majority 
of the CPGs’ recommendations and approved them as 
the final recommendations. However, those with no 
agreement upon were discussed, reviewed and revised, 
and the final recommendations were composed as 
follows:
Recommendations for Screening, Risk Factors 
and Follow‑up
Recommendation for vitamin D
This recommendation was primarily described as 
“Vitamin D level is recommended to be checked in 
diabetics and treatment is advised for vitamin D 
deficient patients to decrease the risk of developing DR”. 
However, vitamin D administration is not completely in 
the field of ophthalmology and could result in adverse 
effects in some patients. Therefore, this recommendation 
was ultimately revised to “As vitamin D deficiency 
can be associated with progression of DR, consultation 
with a specialist (endocrinologist or gastroenterologist, 
or nephrologist) is warranted for diabetic patients 
with vitamin D deficiency and coexisting renal and 
gastrointestinal problems.” in order to share the 
responsibility of correcting Vitamin D with other 
specialists; hence minimizing the adverse outcomes.
Recommendations for Diagnosis
Recommendation for precautions for fluorescein angiography
Considering the large number of patients in whom 
fluorescein angiography is recommended, this 
recommendation was reviewed and after taking patients 
safety and consultation costs into account was revised 
from “Relevant consultations are recommended prior 
to performing fluorescein angiography in patients with 
history of heart and vascular problems, drug allergy, 
and lung and kidney diseases” to “It is recommended 
that patients with known history of cardiovascular 
diseases, allergy, and lung or kidney disorders have 
appropriate consultation before undergoing fluorescein 
angiography”.
Recommendation for different types of fluorescein 
angiography
This recommendation was primarily described as 
“Wide‑field fluorescein angiography is superior for 
peripheral retinal lesions and could alter patient’s 
classification and impact treatment and follow‑up 
plans”. However, with respect to the experts’ opinion, 
clinical preferences, and costs, this recommendation was 
reviewed and the indications became clearer and the 
ultimate recommendation was changed to “Wide-field 
fluorescein angiography is superior in cases with 
peripheral retinal lesions as it could alter the classification 
of the DR and therapeutic and follow‑up approaches. 
Availability of wide-field fluorescein angiography can 
be limited to the major ophthalmology centers”.
Recommendation for other imaging modalities
With respect to the consensus reached and the viewpoints 
of the technical committee of the Ministry of Health and 
Medical Education, the recommendation for retinal 
imaging underwent major revision and the final version 
was composed.
The primary recommendation was as follows:
“New imaging techniques for retinopathy include 
Heidelberg retina angiograph (HRA), optical coherence 
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tomography (OCT), retinal thickness analyzer (RTA) and 
fundus autofluorescence (FAF).
a. OCT in DR is recommended for the following 
scenarios:
1. Macular thickness measurements, follow‑up or 
treatment of macular edema
2. To diagnose tractional macular thickening.
b. HRA, as an angiographic tool has the following 
characteristics:
1. Providing digital images
2. High speed angiography
3. High resolution.
c. FAF is employed for evaluating the functional RPE 
changes without need to inject any dye.”
It is recommended to use these imaging tools, for the 
above‑mentioned purposes with exception of RTA that 
has no clinical application.
However, following experts’ consensus and 
considering the professional suggestions of the 
mentioned committee to specify the clinical application 
of the recommendation, the recommended conditions 
for using OCT were revised. In addition, specific 
characteristics of the new fluorescein angiography 
techniques including high speed, high resolution, and 
saving images in digital format were described. The 
application of FAF was also defined more precisely and 
the final version was composed as follows:
“New imaging modalities for evaluation of DR include 
new angiographic, retinal thickness analysis (RTA) 
techniques, optical coherence tomography (OCT) and 
fundus autofluorescence (FAF).
• Due to the particular properties of OCT such as 
demonstrating different layers of retina, the use of 
OCT it is recommended to be used in the following 
conditions:
o To determine the macular thickness in diabetic 
macular edema (before and after treatment)
o To detect vitreoretinal traction or any membrane 
on the macula.
• Due to the particular properties of new fluorescein 
angiography techniques (SLO [Scanning Laser 
Ophthalmoscopy] Angiography) such as high‑speed 
imaging, high resolution, possibility of digitally 
storing the images, and integrating the patients’ data 
from different medical centers, it is suggested that 
these imaging modalities be available in the majority 
of public and private settings.
• FAF can investigate functional changes in retinal 
pigment epithelium (RPE) without the injection.”
Recommendations for Treatment
Recommendations for treatment are the most important 
part in this clinical guideline, therefore the customization 
team revised them multiple times based on the experts’ 
opinions.
Recommendation for indications of macular laser treatment
This recommendation was primarily written as 
follows:
“Macular Laser treatment is recommended in the 
following scenarios:
1. Presence of CSME according to ETDRS study
2. One of the following conditions even in the absence 
of diagnostic criteria for CSME:
o Macular edema progressing to central macula 
(leaking upper macular lesions, hard exudate 
approaching the central macula)
o In patients incapable of regular follow‑up every 
3 months
o Cataract surgery candidates (in patients with 
cataract who have leaking macular lesions in 
their fundus, laser treatment of macular edema 
is recommended before the cataract surgery)
o Permanent vision loss in the fellow eye as a result 
of CSME
o In PRP candidates, laser treatment of macula is 
recommended prior to or concurrent with PRP 
to prevent worsening of macular edema.”
This recommendation was revised to emphasize on 
intravitreal anti‑VEGF injections as one of the principal 
treatments for macular edema as below:
“Macular laser photocoagulation should be considered 
in the following conditions:
• Presence of clinically significant macular edema 
(CSME) according to ETDRS.
(More recent studies recommend intravitreal injection 
of anti‑VEGF in cases with center involving macular 
edema and visual acuity of less than 20/30 to 20/40; 
however, if the macular center is spared and visual 
acuity is higher than 20/30 to 20/40, macular laser 
photocoagulation can be applied.)
• Any of the following conditions even in the absence 
of CSME features:
o Progression of macular edema towards the central 
parts of the macula
o Patients who cannot be followed every 3 months
o Cataract surgery candidates with leaking macular 
lesions may receive macular laser treatment 
preoperatively.
o Permanent vision loss in the fellow eye due to 
CSME.
o In order to prevent aggravation of macular 
edema, PRP candidates with coexisting diabetic 
macular edema (DME) should receive intravitreal 
anti‑VEGF injection prior to undergoing laser 
treatment.”
Recommendation for follow‑up after macular laser 
photocoagulation
The primary recommendation of the customization team 
for follow‑up after laser treatment of the macula was: 
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“After laser treatment for macular edema, follow‑up 
is recommended every 2-4 months until stabilization 
of the condition. Subsequent laser retreatment will be 
planned based on visual acuity (better than 20/30) and 
no involvement of central fovea.” According to the 
Ministry of Health and Medical Education Technical 
Committee, the reason of disagreement in the consensus 
process was re‑evaluated. For this purpose and in 
order to make this recommendation more practical, a 
determinant VA for retreatment was extracted from 
two valid references;[215,135] VA of “20/30” was replaced 
by “20/30 or 20/40” and the final recommendation was 
composed as:
“According to DRS and ETDRS, patients should 
be followed at 2‑4 months intervals after macular 
laser treatment; decision for retreatment will be based 
on visual acuity (better than 20/30 or 20/40) and 
involvement of the central fovea thereafter.”
Recommendation for new laser therapy techniques
Considering the high cost of the instrument equipped 
with minimal invasive subthreshold technique, the initial 
recommendation “Considering the availability, lower 
rate of retinal damage and the higher speed of laser 
procedure with the retinal laser platform by the minimal 
invasive subthreshold technique, it is recommended 
for ophthalmologists to use the above‑mentioned 
retinal laser platform” was replaced by “Considering 
the lower risk of retinal damage with minimally 
invasive subthreshold technique, a limited number of 
laser machines equipped with these technologies are 
recommended to be available in ophthalmology centers”.
In conclusion, customized diabetic retinopathy clinical 
practice guidelines for Iranian population was composed 
by applying the higher grade existing evidence in the 
literature, the opinions of Iranian medical universities’ 
faculty members under technical supervision of the 
Office for Healthcare Standards, Deputy of Curative 
Affairs, Iran Ministry of Health and Medical Education. 
Hence, in addition to fulfilling strategic objective No. 75 
of this ministry, the provided recommendations can 
standardize the screening, referral, diagnosis, treatment 
and follow‑up of patients with diabetic retinopathy.
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